The big pharmaceutical companies have been taking a lot of heat, at least on the growth side of the equation. Investors have assumed that global stagnation and domestic health-care limbo clouds the future, along with expiring patents...but not all Big Pharma is created equal, writes Stephen Leeb of Income Performance .